Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05710315 · ClinicalTrials.gov registry record · NA
Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
A NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05710315: Recruiting NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure, sponsored by Inova Health Care Services.
NCT05710315 is a NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 32 participants, below the 1,221-participant average among 7 other Exocrine Pancreatic Insufficiency trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05710315, a NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat and helps the body absorb it. The device connects with tube feedings to help the body with digestion. RELiZORB™ is approved by the U.S. Food and Drug Administration (FDA) for use with tube feedings in patients 5 years of age or older. While the use of RELiZORB™ in this study is consistent with the FDA approval, the use of RELiZORB™ in patients with multi organ failure is not in the current standard of care practice at Inova Health Care facilities.
Primary Outcome
Efficacy will be assessed by the total calories administered, expressed as the percentage of goal nutrition calories achieved daily, compared between the two groups over the five-day study period
Conditions Studied
Interventions
- OTHER Placebo
- DEVICE RELiZORB™
Study Locations (1)
Virginia
- Inova Fairfax Medical Campus - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT05710315 shows while recruiting
NCT05710315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,221-participant average among 7 other Exocrine Pancreatic Insufficiency trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Exocrine Pancreatic Insufficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05710315 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05710315 about?
NCT05710315 is a clinical study titled "Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure". The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat a...
What is the current status of trial NCT05710315?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2025-05-07. Estimated completion is 2026-05-31.
What conditions does trial NCT05710315 study?
This clinical trial studies the following conditions: Exocrine Pancreatic Insufficiency, Multi Organ Failure.
What interventions are being tested in trial NCT05710315?
The interventions under investigation include: Placebo (OTHER), RELiZORB™ (DEVICE).
Who is sponsoring clinical trial NCT05710315?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05710315 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exocrine Pancreatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
RECRUITING
-
THE Malabsorption Blood Test Trial Will Help Determine THE Benefits OF Pancreatic Enzyme Replacement Therapy IN Patients With Mild TO Moderate Exocrine Pancreatic Insufficiency.
RECRUITING · Phase 4
-
Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency
RECRUITING · Phase 4
-
PR-018: An Open-Label, Safety Extension of Study PR-011
COMPLETED · Phase 4
-
Open-Label Phase III Long-Term Safety Trial of Liprotamase
COMPLETED · Phase 3
-
SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI